Do higher drug costs lead to better health? – A rebuttal

Main Article Content

Donald Han
Edward C. Y. Wang

Keywords

LETTER TO THE EDITOR

Abstract

The authors Mintzes and Lexchin1 in their commentary to our paper titled The Value of Medicines in Canada,2 have cultivated a theme to which we both agree – the need for efficient use of drug therapy. It is our original position that innovative pharmaceuticals, when used appropriately as part of overall disease management, offer value-for-money by increasing both the global quality and quantity of life

Abstract 84 | PDF Downloads 28

References

1. Mintzes B, Lexchin J. Do Higher Drug Costs Lead to Better Health? Can J Clin Pharmacol 2005;12(1):e22-e27.
2. Han D, Wang ECY. The Value of Medicines in Canada. Can J Clin Pharmacol 2005;12 (1):e10- e21.
3. Canadian Institute for Health Information. National health expenditure trends, 1975-2002. Ottawa, ON: CIHI, 2002.
4. Policy Research Division, Strategic Policy Directorate, Population and Public Health Branch, Health Canada. Economic burden of illness in Canada, 1998.2002.
5. Guide to Community Preventive Services. http://www.thecommunityguide.org Accessed December 15, 2003.
6. Canadian Task Force on Preventive Health Care. http://www.ctfphc.org. Accessed January, 2005.
7. Patented Medicines Pricing Review Board. Annual Report 2003. Available at http://pmprb.com/english/View.asp?x=302&mp=91 Accessed January, 2005
8. Calfee, JE. Prices, Markets, and the Pharmaceutical Revolution. Washington DC: American Enterprise Institute Press, 2000.
9. DiMasi J, Paquette C. The Economics of Follow-on Drug Research and Development Trends in Entry Rates and the Timing of Development. Pharmacoeconomics 2004;22(Suppl.2):1-14.
10. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. Journal of Health Economics 2003;22(2):151-185